This trial is active, not recruiting.

Condition gastric cancer
Sponsor National University Hospital, Singapore
Start date September 2011
End date December 2014
Trial identifier NCT01100814, GA01/08/08


The investigators hypothesize that aberrant hypermethylation of tumour suppressor genes is an important mechanism for Epstein-Barr Virus (EBV) - related gastric carcinogenesis, the promoter hypermethylation status and the expression of S100A2 and TFF1 might be different between EBV-associated gastric cancer (GC) and non EBV-associated GC.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective cross-sectional

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Nil Exclusion Criteria: - Nil

Additional Information

Official title Expression of S100A2 and Trefoil Factor Family Members in Epstein-Barr Virus Related Gastric Cancer
Trial information was received from ClinicalTrials.gov and was last updated in January 2014.
Information provided to ClinicalTrials.gov by National University Hospital, Singapore.